Catherine A. Sohn
CIK: 0001555132
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- May 1, 2026ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
48.8K shares- - Jan 7, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct2.9K shares at avg. $10.42$30K - Jan 7, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct3.3K shares at avg. $10.42$34K - Jan 7, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct26.9K shares at avg. $39.11$1.1M - Jan 7, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct20.7K shares at avg. $10.42$216K - Jan 6, 2026MAZE
Maze Therapeutics, Inc.
Sale(S)Direct2.5K shares at avg. $38.62$96K - Jan 6, 2026MAZE
Maze Therapeutics, Inc.
Exercise(M)Direct2.5K shares at avg. $10.42$26K - Jan 5, 2026ALT
Altimmune, Inc.
Purchase(P)Direct500 shares at avg. $4.24$2K - Sep 25, 2025ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
48.8K shares- - Sep 22, 2025MAZE
Maze Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
18K shares- - Mar 17, 2025ALT
Altimmune, Inc.
Purchase(P)Direct1K shares at avg. $5.78$6K - Feb 6, 2025ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
18.6K shares- - Sep 26, 2024ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
34.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 1, 2026 |  ALT Altimmune, Inc. | Award(A) Stock Options (option to buy) | 48,800 | - | - | Direct |
| Jan 7, 2026 |  MAZE Maze Therapeutics, Inc. | Exercise(M) | 2,895 | $10.42 | $30,166 | Direct |
| Jan 7, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 3,281 | $10.42 | $34,188 | Direct |
| Jan 7, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 26,920 | $39.11 | $1,052,785 | Direct |
| Jan 7, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 20,744 | $10.42 | $216,152 | Direct |
| Jan 6, 2026 | MAZE Maze Therapeutics, Inc. | Sale(S) | 2,493 | $38.62 | $96,270 | Direct |
| Jan 6, 2026 | MAZE Maze Therapeutics, Inc. | Exercise(M) | 2,493 | $10.42 | $25,977 | Direct |
| Jan 5, 2026 | ALT Altimmune, Inc. | Purchase(P) | 500 | $4.24 | $2,118 | Direct |
| Sep 25, 2025 | ALT Altimmune, Inc. | Award(A) Stock Options (option to buy) | 48,800 | - | - | Direct |
| Sep 22, 2025 | MAZE Maze Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 18,000 | - | - | Direct |
| Mar 17, 2025 | ALT Altimmune, Inc. | Purchase(P) | 1,000 | $5.78 | $5,785 | Direct |
| Feb 6, 2025 | ALT Altimmune, Inc. | Award(A) Stock Options (option to buy) | 18,600 | - | - | Direct |
| Sep 26, 2024 | ALT Altimmune, Inc. | Award(A) Stock Options (option to buy) | 34,900 | - | - | Direct |
1-13 of 13 transactions
About Sohn Catherine A.
Sohn Catherine A. (SEC CIK 0001555132) files insider reports with the SEC as Director of Altimmune, Inc. (ALT) and Director of Maze Therapeutics, Inc. (MAZE).
Signal8 holds 9 ownership filings by Sohn Catherine A. (1 Form 3, 8 Form 4), filed between Sep 30, 2024 and May 1, 2026. Those filings report 13 transactions, from Sep 26, 2024 to May 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Sohn Catherine A.'s filings is in GAITHERSBURG, MD.
Recent filings by Sohn Catherine A.
- May 1, 2026: Grant or award of ALT derivative securities (Form 4, code A).
- Jan 7, 2026: Option exercises of MAZE shares (2 lines, Form 4, code M).
- Jan 7, 2026: Open-market sale of MAZE shares (Form 4, code S).
- Jan 7, 2026: Option exercise of MAZE shares (Form 4, code M).
- Jan 6, 2026: Open-market sale of MAZE shares (Form 4, code S).
Other insiders filing for Altimmune, Inc. (ALT)
- Arbet-Engels Christophe, Chief Medical Officer
- WEAVER GREGORY L, Chief Financial Officer
- MENZIUSO RICHARD THOMAS, Principal Accounting Officer
- Richardson Linda M, Chief Commercial Officer
- Durso Jerome Benedict, President and CEO
- Roberts M Scot, Chief Scientific Officer